Medifron DBT Co. Ltd Cash Flow-to-Debt Ratio
Medifron DBT Co. Ltd cash flow-to-debt ratio. Medifron DBT Co. Ltd (065650) has a Cash Flow-to-Debt Ratio of -0.15x as of September 2025, meaning its operating cash flow of ₩-12.73 Billion could theoretically repay 0% of its total liabilities (₩86.61 Billion) in one year. Check earnings quality score of Medifron DBT Co. Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Medifron DBT Co. Ltd (2014–2024)
Cash flow-to-debt ratio of Medifron DBT Co. Ltd from 2014 to 2024. Historical debt coverage capacity for Medifron DBT Co. Ltd across 11 annual periods. Check how aggressively does Medifron DBT Co. Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Medifron DBT Co. Ltd Cash Flow-to-Debt Ratio by Year (2014–2024)
Medifron DBT Co. Ltd cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Medifron DBT Co. Ltd. For the full cash flow conversion analysis, see Medifron DBT Co. Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.11x | ₩-4.54 Billion | ₩42.92 Billion | ▲ +6.6% |
| 2023 | -0.11x | ₩-2.14 Billion | ₩18.89 Billion | ▲ +4.2% |
| 2022 | -0.12x | ₩-2.91 Billion | ₩24.66 Billion | ▲ +46.5% |
| 2021 | -0.22x | ₩-1.50 Billion | ₩6.81 Billion | ▼ -155.3% |
| 2020 | -0.09x | ₩-1.67 Billion | ₩19.36 Billion | ▲ +96.4% |
| 2019 | -2.42x | ₩-4.28 Billion | ₩1.77 Billion | ▼ -574.2% |
| 2018 | -0.36x | ₩-852.48 Million | ₩2.37 Billion | ▲ +54.2% |
| 2017 | -0.78x | ₩-1.17 Billion | ₩1.49 Billion | ▼ -48.2% |
| 2016 | -0.53x | ₩-1.15 Billion | ₩2.18 Billion | ▼ -2085.2% |
| 2015 | -0.02x | ₩-170.27 Million | ₩7.04 Billion | ▼ -5408.5% |
| 2014 | 0.00x | ₩701.96K | ₩1.54 Billion | — |